719927
Resomer® RG 756 S, Poly(D,L-lactide-co-glycolide)
ester terminated, lactide:glycolide 75:25, Mw 76,000-115,000
Synonym(s):
PLGA
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
[C3H4O2]x[C2H2O2]y
CAS Number:
MDL number:
UNSPSC Code:
12162002
NACRES:
NA.23
Quality Level
form
amorphous
feed ratio
lactide:glycolide 75:25
mol wt
Mw 76,000-115,000
degradation timeframe
<6 months
viscosity
0.71-1.0 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer)
transition temp
Tg 49-55 °C
storage temp.
2-8°C
SMILES string
O2C(C(=O)OC(C2=O)C)C.O1CC(=O)OCC1=O
InChI
1S/C6H8O4.C4H4O4/c1-3-5(7)10-4(2)6(8)9-3;5-3-1-7-4(6)2-8-3/h3-4H,1-2H3;1-2H2
InChI key
LCSKNASZPVZHEG-UHFFFAOYSA-N
Application
Poly (lactic-co-glycolic acid) 75:25 copolymer may be used to design a controlled drug delivery implant.
Controlled release
Legal Information
Product of Evonik
RESOMER is a registered trademark of Evonik Rohm GmbH
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
An in-situ forming implant formulation of naltrexone with minimum initial burst release using mixture of PLGA copolymers and ethyl heptanoate as an additive: In-vitro, ex-vivo, and in-vivo release evaluation.
Kamali H, et al.
Journal of drug delivery science and technology, 47, 95-105 (2018)
Rongcai Liang et al.
International journal of pharmaceutics, 454(1), 344-353 (2013-07-23)
Peptide or protein degradation often occurs when water flows into the dosage form. The aim of this study was to investigate the effect of water on exenatide acylation in poly(lactide-co-glycolide) (PLGA) microspheres. Exenatide-loaded PLGA microspheres were incubated at different relative
Maria Kirzhner et al.
Ophthalmology, 120(6), 1300-1304 (2013-02-13)
To compare wrapped and polymer-coated hydroxyapatite implants in children undergoing primary enucleation with no adjuvant therapies. Retrospective, interventional cohort study. All children undergoing primary enucleation without adjuvant therapies between 1999 and 2009 at a tertiary pediatric cancer hospital. Review and